Capravirine
Appearance
![]() | |
Names | |
---|---|
Preferred IUPAC name
{5-[(3,5-Dichlorophenyl)sulfanyl]-4-(propan-2-yl)-1-[(pyridin-4-yl)methyl]-1H-imidazol-2-yl}methyl carbamate | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H20Cl2N4O2S | |
Molar mass | 451.37 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer.[1][2] Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.[3][4]
References
- ^ PubChem. "Capravirine". pubchem.ncbi.nlm.nih.gov. Retrieved 2019-06-02.
- ^ "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
- ^ "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
- ^ "A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 23 June 2005. Retrieved 2019-06-02.